HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study

The treatment of hepatocellular carcinoma (HCC) patients exhibiting high-risk characteristics (Vp4, and/or bile duct invasion, and/or tumor occupancy  ≥ 50%) lacks standardized approaches and yields unfavorable...

Source: BMC Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Xu Chang, Xinge Li, Peng Sun, Zhenfeng Li, Pengfei Sun and Shangkun Ning Tags: Research Source Type: research